Factory Supply Cinnarizine Powder Intermediate Cinnarizine Powder Cinnarizine

• Customization: Available
• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Solid
• Purity: >99%
• Name: Cinnarizine Powder
• Appearance: White Powder
• Color: White
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical;Analgesic;Antiplatelet
• Specific: COA
• Test Method: HPLC 99%
• Shelf Life: 2 Years
• CAS No.: 298-57-7
• Mf: C26h28n2
• MW: 368.51
• Melting Point: 117-120°c
• Density: 1.1818 (Rough Estimate)
• Product Name: Cinnarizine
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-sung
• Origin: Shaanxi Xi′an
• HS Code: 2933599090
• Production Capacity: 10000kg/Month

Product Description

 

Product Description

Factory supply Cinnarizine powder Intermediate  Cinnarizine powder Cinnarizine

Product Description

Product Details

Product name	Cinnarizine
Cas number	298-57-7
Apperance	White powder
MF	C26H28N2
MW	368.51

Cinnarizine is a medication derivative , and characterized as an antihistamine and a calcium channel blocker, it is also known to promote cerebral blood flow, and so is used to treat cerebral apoplexy, post-trauma cerebral symptoms, and cerebral arteriosclerosis. However, it is more commonly prescribed for nausea and vomiting due to motion sickness or other sources such as chemotherapy, vertigo, or Ménière's disease. Cinnarizine was first synthesized by Janssen Pharmaceutica in 1955. The nonproprietary name is derived from the cinnamyl substituent on one of the nitrogen atoms, combined with the generic ending "-rizine" for "antihistaminics/cerebral (or peripheral) vasodilators". It is not available in the United States or Canada. It is manufactured and marketed in Bangladesh under the trade name Suzaraon by Rephco Pharmaceuticals Limited. It has also been cited as one of the most used drugs for seasickness within the British Royal Navy.

Application&Function

1. Treatment of cytomegalovirus retinitis during induction and maintenance in immunodeficiency patients
(including AIDS patients).
2. Prevention of cytomegalovirus infection in patients receiving organ transplantation and prevention of
cytomegalovirus disease in AIDS patients with cytomegalovirus positive serum test.

Specification